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Objectives: To assess the contributions of cortico-juxtacortical and corpus callosum lesions to
multiple sclerosis diagnosis and to compare the value of $1 vs $3 periventricular lesions in
clinically isolated syndromes (CIS).
Methods: Step 1: We evaluated lesion topography classifications in 657 patients with CIS with
stepwise Cox proportional hazards regression models considering second attack as the outcome.
Step 2: We established 2 dissemination in space (DIS) versions according to the periventricular
lesion cutoffs of $1 and $3 and assessed their performance at 10 years with second attack
as the outcome, first individually and then combined with dissemination in time (DIT) in all cases
(n 5 326), by age, and by CIS topography.
Results: Step 1: The models (hazard ratios [95% confidence interval]) favored $1 over $3 peri-
ventricular lesions (2.5 [1.7–3.6]) and cortico-juxtacortical over juxtacortical lesions (1.4 [1.0–
1.8]). Callosal lesions were not selected. Step 2: DIS specificity with $1 periventricular lesions
was slightly lower than with $3 (59.1 vs 61.4) and the same after adding DIT (88.6). Regarding
age, $3 periventricular lesions improved DIS specificity over $1 lesions in the 40–49 years of
age bracket (66.7 vs 58.3). This difference disappeared when adding DIT (83.3). Optic neuritis
had a similar pattern when evaluating CIS topographies.
Conclusions: Our results comply with the Magnetic Resonance Imaging in Multiple Sclerosis
(MAGNIMS) consensus recommendation of combining cortical and juxtacortical lesions into a sin-
gle term when possible. Concerning periventricular lesions, maintaining the current $1 cutoff in
the McDonald criteria does not compromise specificity in typical CIS cases, but attention should
be paid to older patients or optic neuritis cases. Neurology® 2017;89:2351–2356
GLOSSARY
CC5 corpus callosum; CIS5 clinically isolated syndrome; CJC5 cortical and juxtacortical; DIR5 double inversion recovery;
DIS 5 dissemination in space; DIT 5 dissemination in time; EDSS 5 Expanded Disability Status Scale; FLAIR 5 fluid-
attenuated inversion recovery; Gd 5 gadolinium; JC 5 juxtacortical; MAGNIMS 5 Magnetic Resonance Imaging in Multiple
Sclerosis; MS 5 multiple sclerosis; PV 5 periventricular; SC 5 spinal cord.
Recently, an expert opinion consensus on proposed modifications to the multiple sclerosis (MS)
diagnostic criteria suggested the increase of periventricular (PV) lesions from$1 to$3 and the
inclusion of cortical, optic nerve, and symptomatic lesions for determining dissemination in
space (DIS).1 Previous publications showed the relevance of lesion topographies for MS diag-
nosis2,3 or reassessed the role of PV lesion number.4 Regarding cortical lesions, they can be
identified using nonconventional MRI and were proposed as part of the DIS criteria before,5 but
interobserver variability is high.6 In this sense, the expert opinion consensus proposed
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combining cortical and juxtacortical (JC) le-
sions into a single term (CJC). Finally, corpus
callosum (CC) lesions are common in MS but
do not appear to contribute to the diagnosis.7
Therefore, the objective of this study was to
assess the contributions of CJC and CC le-
sions to MS diagnosis and to compare the
value of $1 vs $3 PV lesions, additionally
stratified by age or clinically isolated syndrome
(CIS) topography, in CIS.
METHODS Study cohort. This study was based on a longitu-
dinal, open CIS cohort at the MS Centre, Vall d’Hebron Uni-
versity Hospital, Barcelona, Spain, following a protocol described
elsewhere.3,8 Briefly, we included patients ,50 years of age first
seen within 3 months of the CIS. We recorded demographic data,
CIS topography, presence of oligoclonal bands, and disability
according to the Expanded Disability Status Scale (EDSS) at
baseline, and performed follow-up visits every 3–6 months as-
sessing for relapses and disability according to the EDSS mea-
sured during stability periods. Concerning additional MRI
acquisition and analysis for this study, transverse or sagittal 3D
double inversion recovery (DIR) sequences were performed since
2010. One of two experienced neuroradiologists (C.A., A.R.)
blinded to clinical follow-up assessed the MRI scans during the
daily clinical practice. In doubtful cases, the final analysis was
based on their consensus opinion. They scored the number and
location of lesions on T2-weighted images and the number of
gadolinium (Gd)–enhancing lesions on brain MRI. From 2006,
we recorded the presence of CC lesions on T2–fluid-attenuated
inversion recovery (FLAIR) sagittal sequences prospectively in the
CIS database. We constructed the CJC variable by combining
supratentorial JC and intracortical lesions and assessed it on DIR
and T2-FLAIR images. Importantly, we defined PV lesions as
those in contact with the lateral or third ventricles, but not when
in contact with the fourth ventricle. CC lesions were not con-
sidered PV unless they extended outside the CC, and we only
considered a lesion to be callosal when identified in 3–5 mid-
sagittal images (with a 3-mm slice thickness), therefore excluding
those that were paracallosal and thus considered PV. Finally, from
2007, we scored lesion number and presence of Gd enhancement
on spinal cord (SC) MRI systematically.
Experimental design. Step 1. To evaluate the effect of individual
lesion topographies, we selected patients with sufficient information
on baseline brain MRI to assess DIS and dissemination in time
(DIT) according to the 2010 McDonald criteria (n 5 657). Next,
we established the following lesion topography classifications: $1
PV, $3 PV, $1 JC, $1 CJC, $1 CC, $1 infratentorial, and
$1 SC.We then ran univariable and multivariable Cox proportional
hazards regression models using a forward and backward stepwise
analysis with likelihood ratio statistics (p value for entry of 0.05
and p value for removal of 0.1) considering second attack as the
outcome during the total follow-up time. We added a “missing”
category for patients with no recorded SC or CC lesions. We used
bootstrap resampling to cope with overfitting.
Step 2. To evaluate performance, we selected cases from step 1
with a minimum follow-up of 10 years or a second attack within 10
years of the CIS9 (n5 326). We constructed the 2010 DIS criteria10
taking into account the symptomatic lesions11,12 and using the CJC
topography (according to the results from step 1). Next, we estab-
lished 2 DIS versions according to the PV lesion cutoffs of $1 and
$3. We then assessed the sensitivity, specificity, accuracy, positive
predictive value, and negative predictive value of both DIS versions,
first individually and then combined with DIT, with second attack at
10 years as the outcome. Finally, we evaluated the performance of$1
and$3 PV lesions as part of DIS alone and DIS plus DIT according
to age (40–49, 30–39, 20–29, and #19 years) and CIS topography
(optic nerve, infratentorial, SC, and other, which can include mul-
tifocal or hemispheric syndromes).
Statistical tests were performed on the 0.05 level of signifi-
cance using IBM SPSS Statistics (SPSS Inc., Chicago, IL), version
22.0.
Standard protocol approvals, registrations, and patient
consents. This study received approval from the Clinical
Research Ethics Committee at Vall d’Hebron University Hospi-
tal. All patients signed written informed consents.
RESULTS From January 1995 to January 2016, we
included 1,214 patients in the CIS cohort. Of these,
we excluded 71 (5.8%) during follow-up for having
presented a previous demyelinating attack (n 5 13),
exceeding the age limit (n 5 4), exceeding the entry
window (n5 26), or reaching an alternative diagnosis
(n 5 28). Of the remaining 1,143 patients, 657
fulfilled the criteria for step 1 and 326 fulfilled the
criteria for step 2.
Step 1. Baseline characteristics. Of the 657 patients,
66.5% were female, and they had a mean (SD) age of
32.2 (8.0) years. The baseline brain MRI was abnormal
in 75.5%. During a mean follow-up of 6.5 (4.2) years,
282 (42.9%) presented a second attack (table 1).
Effect of individual lesion topography classifications.
Table 2 shows the number of patients fulfilling
each type of lesion topography classification, the
Table 1 Baseline characteristics of the studied cohorts
Step 1 (n 5 657) Step 2 (n 5 326)
Female, n (%) 437 (66.5) 227 (69.6)
Mean (SD) age, y 32.2 (8.0) 31.5 (7.9)
CIS topography, n (%)
Optic nerve 219 (33.3) 92 (28.2)
Brainstem 179 (27.2) 92 (28.2)
Spinal cord 180 (27.4) 101 (31.0)
Other 79 (12.0) 41 (12.6)
OB present, n (%)a 335 (59.3) 211 (72.5)
Abnormal baseline brain MRI, n (%) 496 (75.5) 293 (89.9)
Abnormal baseline SC MRI, n (%)b 172 (52.3) 76 (66.1)
Gd enhancement on brain MRI, n (%) 191 (29.1) 127 (39.0)
Gd enhancement on SC MRI, n (%)b 54 (16.4) 28 (24.3)
Mean (SD) follow-up, y 6.5 (4.2) 9.0 (3.8)
DMT before second attack, n (%) 184 (28.0) 101 (31.0)
Abbreviations: CIS 5 clinically isolated syndrome; DMT 5 disease-modifying treatment;
Gd 5 gadolinium; OB 5 oligoclonal bands; SC 5 spinal cord.
aOB: n 5 565 in step 1, n 5 291 in step 2.
bSC MRI: n 5 329 in step 1, n 5 115 in step 2.
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proportion presenting a second attack, and their cor-
responding hazard ratios (95% CI). Both stepwise
models confirmed the significant contributions of
$1 PV, $1 CJC, and $1 infratentorial lesions;
$1 SC lesions remained in the second to last back-
ward step (1.5 [1.0–2.2]; p 5 0.045). Bootstrap
showed no overfitting in our models (bias from
20.008 to 0.009).
Step 2. Baseline characteristics. Of the 326 patients,
69.6% were female, and they had a mean (SD) age
of 31.5 (7.9) years; the baseline brain MRI was abnor-
mal in 89.9%. Gd enhancement was demonstrated in
39.0% of brain and 24.3% (n5 28/115) of SC scans.
During a mean follow-up of 9.0 (3.8) years, 86.5%
presented a second demyelinating attack. Disease-
modifying treatment was started before the second
attack in 31.0% (table 1). The proportion of patients
treated before the second attack fulfilling DIS with
$1 PV lesions was similar to DIS with$3 PV lesions
(40.3% and 42.5%, respectively), and between DIS
plus DIT with $1 (51.6%) and $3 PV lesions
(52.4%).
Performance of DIS and DIS plus DIT according to the
PV lesion number cutoffs.Concerning the performance
of the modified 2010 criteria, although the specificity
of the criteria with $1 PV lesions was slightly lower
than with$3 PV when assessing DIS (table 3), it was
exactly the same after combining them with DIT
(table 4).
When assessing age groups, $3 PV lesions con-
ferred a higher specificity to DIS than $1 PV lesions
in the 40–49 years of age bracket (table 3). This
difference disappeared when evaluating DIS plus
DIT (table 4). We observed a very similar pattern
in optic neuritis when evaluating CIS topographies
(tables e-1 and e-2 at Neurology.org).
DISCUSSION In step 1, the stepwise multivariable
analyses selected CJC over JC lesions and thus we
used the former topography in our DIS model for
step 2. If also considering the univariable analyses
and the similar proportion of patients with JC and
CJC lesions presenting a second attack, our findings
support the notion that the sharp differentiation
between JC and intracortical lesions is not necessary,
complying with the Magnetic Resonance Imaging in
Multiple Sclerosis (MAGNIMS) consensus recom-
mendation of combining them into a single term1
in specialized institutions where this is possible,
whereas in other centers the determination of JC le-
sions could suffice. Nevertheless, a limitation of our
study is our recent implementation of DIR (2010),
which could lead to missing patients with intracort-
ical lesions; hence, further studies are needed to val-
idate these results. Concerning CC lesions, our
negative results coincide with a previous study,7 even
though in our case we did have sagittal images and
T2-FLAIR sequences. Contrary to these findings,
another study did show an effect of CC lesions but
the individual contributions of each lesion topogra-
phy were not taken into account,13 an important issue
since different lesion topographies can coexist.
Nonetheless, our negative results could be influenced
by the lower number of patients with prospectively
recorded CC lesion data. Another possible explana-
tion is that CC lesions are less frequently associated
with Gd enhancement than deep white matter lesions
and, therefore, may not be good predictors for the
development of a second attack.14 Another limitation
in step 1 is the smaller sample size in the case of SC
lesions.
Regarding PV lesions in step 1, the stepwise anal-
yses favored $1 PV over $3 PV lesions. The MAG-
NIMS expert consensus proposed going back to the
3-lesion cutoff,7 based on the detection of incidental
PV lesions in healthy individuals and patients with
other neurologic diseases, and on studies showing that
this lesion threshold could help differentiate MS from
other diseases.1 Although incidental PV lesions could
Table 2 Proportions and hazard ratios (HRs) of the different lesion topographies (n 5 657)
n (%) Second attack, n (%)
Univariable
HR (95% CI) p
HR with forward and backward
stepwise analyses (95% CI) p
‡1 PV 414 (63.0) 232/414 (56.0) 3.7 (2.7–5.0) ,0.0001 2.5 (1.7–3.6) ,0.0001
‡3 PV 356 (54.2) 211/356 (59.3) 3.2 (2.4–4.2) ,0.0001 —
‡1 JC 295 (44.9) 172/295 (58.3) 2.5 (2.0–3.2) ,0.0001 —
‡1 CJC 298 (45.4) 174/298 (58.4) 2.5 (2.0–3.2) ,0.0001 1.4 (1.0–1.8) 0.025
‡1 CC 187/433 (43.2) 84/187 (44.9) 2.0 (1.4–2.7) ,0.0001 —
‡1 IT 328 (49.9) 191/328 (58.2) 2.6 (2.0–3.3) ,0.0001 1.4 (1.1–1.9) 0.013
‡1 SC 172/329 (52.3) 76/172 (44.2) 2.2 (1.5–3.3) ,0.0001 —
Abbreviations: CC 5 corpus callosum; CI 5 confidence interval; CJC 5 cortico-juxtacortical; IT 5 infratentorial; JC 5
juxtacortical; PV 5 periventricular; SC 5 spinal cord.
Outcome: second attack.
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also suggest a radiologically isolated syndrome, it is
important to emphasize the role of specificity
to minimize the risk of overdiagnosing MS, especially
in older patients. Therefore, in step 2 we compared
their performance, observing that in DIS, the $3
cutoff was only 2.3% more specific than $1. Fur-
thermore, when evaluating DIS plus DIT, the diag-
nostic performance was practically the same for both.
These results are in accordance with a more recent
publication that studied the effect of a varying num-
ber of PV lesions in 151 patients with CIS.4 In
addition, another study compared the performance
of the 2010 McDonald criteria and the 2016 MAG-
NIMS proposal, observing an overall lower specificity
for the latter, which includes $3 PV lesions for DIS
(63.1% vs 46.4%, respectively).15
However, when assessing age brackets in our
study, the specificity gap increased to 8.4% favoring
DIS with$3 PV lesions in patients aged 40–49 years.
But once again, when assessing DIS plus DIT, we
found no differences in specificity. The same
occurred with optic neuritis cases when we assessed
Table 3 DIS performance in all cases and by age groups, according to the PV lesion cutoffs (‡1 vs ‡ 3) (total n 5 326)
DIS, n (%)
Second attack in patients






(95% CI) PPV (95% CI) NPV (95% CI)
DIS ‡1 PV
All 236/326 (72.4) 218/236 (92.4) 77.3 (72.0–82.1) 59.1 (43.3–73.7) 74.8 (69.8–79.5) 92.4 (89.4–94.6) 28.9 (22.7–36.0)
40–49 y 45/57 (78.9) 40/45 (88.9) 88.9 (76.0–96.3) 58.3 (27.7–84.8) 82.5 (70.1–91.3) 88.9 (80.3–94.0) 58.3 (35.0–78.4)
30–39 y 84/122 (68.9) 78/84 (92.9) 73.6 (64.1–81.7) 62.5 (35.4–84.8) 72.1 (63.3–79.9) 92.9 (87.2–96.1) 26.3 (17.9–36.9)
20–29 y 97/130 (74.6) 90/97 (92.8) 78.3 (69.6–85.4) 53.3 (26.6–78.7) 75.4 (67.1–82.5) 92.8 (88.1–95.7) 24.2 (15.1–36.5)
£19 y 10/17 (58.8) 10/10 (100.0) 62.5 (35.4–84.8) 100.0 (2.5–100.0) 64.7 (38.3–85.8) 100.0 (69.2–100.0) 14.3 (8.1–23.9)
DIS ‡3 PV
All 221/326 (67.8) 204/221 (92.3) 72.3 (66.7–77.5) 61.4 (45.5–75.6) 70.9 (65.6–75.7) 92.3 (89.1–94.6) 25.7 (20.4–31.9)
40–49 y 41/57 (71.9) 37/41 (90.2) 82.2 (68.0–92.0) 66.7 (34.9–90.1) 78.9 (66.1–88.6) 90.2 (80.4–95.4) 50.0 (32.2–67.8)
30–39 y 77/122 (63.1) 71/77 (92.2) 67.0 (57.2–75.8) 62.5 (35.4–84.8) 66.4 (57.3–74.7) 92.2 (86.1–95.8) 22.2 (15.2–31.3)
20–29 y 93/130 (71.5) 86/93 (92.5) 74.8 (65.8–82.4) 53.3 (26.6–78.7) 72.3 (63.8–79.8) 92.5 (87.6–95.5) 21.6 (13.5–32.8)
£19 y 10/17 (58.8) 10/10 (100.0) 62.5 (35.4–84.8) 100.0 (2.5–100.0) 64.7 (38.3–85.8) 100.0 (69.2–100.0) 14.3 (8.1–23.9)
Abbreviations: CI 5 confidence interval; DIS 5 dissemination in space; NPV 5 negative predictive value; PPV 5 positive predictive value; PV 5
periventricular.
Outcome: second attack at 10 years. Modifications to the criteria include symptomatic lesions and $1 cortical and juxtacortical lesions.









(95% CI) Accuracy (95% CI) PPV (95% CI) NPV (95% CI)
DIS 1 DIT ‡1 PV
All 128/326 (39.3) 123/128 (96.1) 43.6 (37.8–49.6) 88.6 (75.4–96.2) 49.7 (44.1–55.3) 96.1 (91.4–98.3) 19.7 (17.5–22.1)
40–49 y 23/57 (40.4) 21/23 (91.3) 46.7 (31.7–62.1) 83.3 (51.6–97.9) 54.4 (40.7–67.6) 91.3 (74.0–97.5) 29.4 (22.3–37.7)
30–39 y 39/122 (32.0) 37/39 (94.9) 34.9 (25.9–44.8) 87.5 (61.7–98.5) 41.8 (32.9–51.1) 94.9 (83.1–98.6) 16.9 (13.9–20.4)
20–29 y 59/130 (45.4) 58/59 (98.3) 50.4 (41.0–59.9) 93.3 (61.7–98.5) 55.4 (46.4–64.1) 98.3 (89.6–99.7) 19.7 (16.4–23.6)
£19 y 7/17 (41.2) 7/7 (100.0) 43.8 (19.8–70.1) 100.0 (2.5–100.0) 47.1 (23.0–72.2) 100.0 (59.0–100.0) 10.0 (6.7–14.6)
DIS 1 DIT ‡3 PV
All 126/326 (38.7) 121/126 (96.0) 42.9 (37.1–48.9) 88.6 (75.4–96.2) 49.1 (43.5–54.6) 96.0 (91.3–98.2) 19.5 (17.3–21.9)
40–49 y 23/57 (40.4) 21/23 (91.3) 46.7 (31.7–62.1) 83.3 (51.6–97.9) 54.4 (40.7–67.6) 91.3 (74.0–97.5) 29.4 (22.3–37.7)
30–39 y 38/122 (31.1) 36/38 (94.7) 34.0 (25.0–43.8) 87.5 (61.7–98.5) 41.0 (32.2–50.3) 94.7 (82.7–98.5) 16.7 (13.7–20.1)
20–29 y 58/130 (44.6) 57/58 (98.3) 49.6 (40.1–59.0) 93.3 (68.1–99.8) 54.6 (45.7–63.4) 98.3 (89.5–99.7) 19.4 (16.1–23.2)
£19 y 7/17 (41.2) 7/7 (100.0) 43.8 (19.8–70.1) 100.0 (2.5–100.0) 47.1 (23.0–72.2) 100.0 (59.0–100.0) 10.0 (6.7–14.6)
Abbreviations: CI 5 confidence interval; DIS 5 dissemination in space; DIT 5 dissemination in time; NPV 5 negative predictive value; PPV 5 positive
predictive value; PV 5 periventricular.
Outcome: second attack at 10 years. Modifications to the criteria include symptomatic lesions and $1 cortical and juxtacortical lesions.
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CIS topography. Altogether, these findings in pa-
tients with typical CIS suggest that, first, the presence
of$1 PV lesions already indicates an increased risk of
presenting a second attack; second, their diagnostic
specificity is high when combined with at least
another typical topography; third, this specificity is
only slightly inferior to $3 PV lesions; and fourth,
their specificity is the same if also considering DIT.
The latter is particularly relevant when taking age into
account, given that the difference in specificity favor-
ing $3 PV lesions in older patients disappears after
adding DIT. Furthermore, this increased specificity
in older patients can be explained by the fact that the
presence of small, focal high-intensity areas surround-
ing the regions around the anterior and posterior pole
of the lateral ventricles, and thin linear hyperinten-
sities along the body of the lateral ventricles on T2-
weighted images, the so-called PV caps and bands, are
a common finding in normal aging.16 However, these
incidental findings are usually symmetric and not
oval-shaped, and should not be confused with the
PV lesions seen in MS.
As for the increased specificity of DIS with$3 PV
lesions in optic neuritis, previous studies demon-
strated that the lower rate of second demyelinating
attacks in this topography compared to others disap-
peared when selecting only the cases with abnormal
brain MRIs17 or when including other risk factors in
the analyses.8 Hence, the higher specificity observed
in DIS with $3 PV lesions could probably be influ-
enced by a higher T2 lesion number at baseline. That
the difference disappears when adding DIT under-
scores the importance of Gd-enhancing lesions for
establishing MS diagnosis.
Importantly, we do not consider it practical to
produce a different set of criteria for older patients
or cases presenting with optic neuritis. Preferably,
we should underscore that the McDonald criteria
were outlined to be applied in patients we suspect
might have MS and that we should always ensure
there is no better diagnostic explanation for the clin-
ical presentation.
Therefore, maintaining the current threshold of
$1 PV lesions in the McDonald criteria does not
compromise specificity in typical CIS cases, but spe-
cial attention should be paid to older patients and
optic neuritis cases.
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